CN100455597C - 高纯度白蛋白生产方法 - Google Patents
高纯度白蛋白生产方法 Download PDFInfo
- Publication number
- CN100455597C CN100455597C CNB2004100575838A CN200410057583A CN100455597C CN 100455597 C CN100455597 C CN 100455597C CN B2004100575838 A CNB2004100575838 A CN B2004100575838A CN 200410057583 A CN200410057583 A CN 200410057583A CN 100455597 C CN100455597 C CN 100455597C
- Authority
- CN
- China
- Prior art keywords
- albumin
- solution
- ion
- albuminous
- purifying
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
Abstract
Description
# | 保留时间(min) | 面积(uV.sec) | 高(uV) |
1 | 0.800 | 3459686 | 219122 |
2 | 1.667 | 418606 | 33569 |
3 | 2.150 | 77883335 | 1963630 |
4 | 3.000 | 6293258 | 122295 |
5 | 20.433 | 297608 | 14424 |
6 | 22.900 | 205822 | 14601 |
7 | 27.567 | 150851 | 10835 |
8 | 31.117 | 2213883 | 170938 |
9 | 37.983 | 164710 | 15088 |
10 | 39.267 | 347946 | 29879 |
11 | 41.750 | 107515 | 8402 |
12 | 42.783 | 2303024 | 192911 |
13 | 43.217 | 139744 | 14141 |
14 | 43.457 | 254521 | 23979 |
15 | 50.467 | 152805 | 13226 |
16 | 50.950 | 162364 | 12577 |
17 | 56.533 | 5753796 | 83674 |
# | 保留时间(min) | 面积(uV.sec) | 高(uV) |
1 | 0.350 | 244385 | 23957 |
2 | 0.633 | 607880 | 45310 |
3 | 0.783 | 3239730 | 243477 |
4 | 0.983 | 1072033 | 158146 |
5 | 2.233 | 76773569 | 2038028 |
6 | 2.933 | 6634089 | 182363 |
7 | 3.733 | 2812688 | 95459 |
8 | 12.483 | 818540 | 20185 |
9 | 12.650 | 218748 | 22750 |
10 | 14.150 | 5423715 | 98336 |
11 | 16.333 | 423403 | 17460 |
12 | 16.633 | 688525 | 24538 |
13 | 17.550 | 2301309 | 84781 |
14 | 18.033 | 1145045 | 47806 |
15 | 19.750 | 672721 | 21562 |
16 | 20.233 | 87799 | 9760 |
17 | 20.700 | 272171 | 13003 |
18 | 21.100 | 862146 | 55792 |
19 | 21.967 | 166471 | 8928 |
20 | 22.883 | 1381445 | 97660 |
21 | 23.583 | 1112632 | 89851 |
22 | 24.000 | 4740347 | 419780 |
23 | 24.417 | 352486 | 26374 |
24 | 24.917 | 171279 | 14625 |
25 | 25.133 | 99734 | 11473 |
26 | 25.267 | 133911 | 10515 |
27 | 25.667 | 223556 | 11854 |
# | 保留时间(min) | 面积(uV.sec) | 高(uV) |
29 | 26.600 | 93906 | 7957 |
30 | 26.817 | 223113 | 18326 |
31 | 27.250 | 303831 | 29461 |
32 | 27.533 | 124218 | 12710 |
33 | 27.783 | 5747091 | 561629 |
34 | 28.550 | 1383761 | 119772 |
35 | 29.033 | 390986 | 33455 |
36 | 29.417 | 182131 | 12713 |
37 | 29.833 | 181333 | 12584 |
38 | 30.183 | 478320 | 30155 |
39 | 30.583 | 1048945 | 58465 |
40 | 31.067 | 3454425 | 214489 |
41 | 31.983 | 168275 | 8663 |
42 | 32.717 | 651406 | 43161 |
43 | 33.150 | 1142221 | 102588 |
44 | 34.017 | 420756 | 23883 |
45 | 35.100 | 115704 | 10008 |
46 | 37.033 | 166588 | 9468 |
47 | 38.267 | 145731 | 8078 |
48 | 38.983 | 781209 | 54029 |
49 | 41.800 | 86967 | 8868 |
50 | 48.883 | 95416 | 8522 |
51 | 50.267 | 174159 | 16737 |
52 | 50.483 | 176115 | 15573 |
53 | 51.267 | 158727 | 13701 |
54 | 52.183 | 297278 | 25795 |
55 | 56.533 | 5846645 | 85710 |
样品 | 序列 |
脱-Leu rHA | LVAASQAALGAWAVARDLGEENFK |
HSA标准品 | AWAVARDLGEENFK+about5%LVAASQAALG |
HSA30℃下12周 | AWAVARDLGEENFK |
rHA4℃下6个月 | AWAVARDLGEENFK |
30℃下6个月 | AWAVARDLGEENFK |
合成的全长和截断C末端肽的混合物 | 1013-LVAASQAALGL900-LVAASQAALG |
脱-Len rHA | 673-AWAVAR900-LVAASQAALG951-DLGEENFK1028-?1140-? |
HSA标准品 | 673-AWAVAR900-LVAASQAALG951-DLGEENFK1028-?1140-? |
rHA于30℃下6个月 | 673-AWAVAR900-LVAASQAALG1028-?1140-?951-无信号 |
金属离子 | 波长 | 原子化温度℃ |
Zn | 213.9 | 1800 |
Cu | 327.4 | 2300 |
Fe | 248.8 | 2400 |
Al | 309.8 | 2500 |
Mn | 279.8 | 2200 |
样品 | A<sub>350</sub> | A<sub>403</sub> | A<sub>500</sub> |
1 | 9.95 | 4.10 | 0.8 |
2 | 9.25 | 5.36 | 1.1 |
3 | 7.40 | 3.26 | 0.6 |
4 | 7.20 | 3.60 | 0.6 |
5 | 8.68 | 4.08 | 0.8 |
6 | 11.45 | 6.26 | 1.2 |
7 | 7.20 | 3.70 | 0.8 |
8 | 6.82 | 4.78 | 1.8 |
Claims (20)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US378,859 | 1995-05-25 | ||
US08/378,859 US5728553A (en) | 1992-09-23 | 1995-05-25 | High purity albumin and method of producing |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB961958243A Division CN1198844C (zh) | 1995-05-25 | 1996-02-29 | 高纯度白蛋白生产方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1611513A CN1611513A (zh) | 2005-05-04 |
CN100455597C true CN100455597C (zh) | 2009-01-28 |
Family
ID=23494845
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2006101006176A Expired - Lifetime CN100443499C (zh) | 1995-05-25 | 1996-02-29 | 高纯度白蛋白生产方法 |
CNB2004100575838A Expired - Lifetime CN100455597C (zh) | 1995-05-25 | 1996-02-29 | 高纯度白蛋白生产方法 |
CNB961958243A Expired - Lifetime CN1198844C (zh) | 1995-05-25 | 1996-02-29 | 高纯度白蛋白生产方法 |
CN03127743A Expired - Lifetime CN100584857C (zh) | 1995-05-25 | 1996-02-29 | 高纯度白蛋白生产方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2006101006176A Expired - Lifetime CN100443499C (zh) | 1995-05-25 | 1996-02-29 | 高纯度白蛋白生产方法 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB961958243A Expired - Lifetime CN1198844C (zh) | 1995-05-25 | 1996-02-29 | 高纯度白蛋白生产方法 |
CN03127743A Expired - Lifetime CN100584857C (zh) | 1995-05-25 | 1996-02-29 | 高纯度白蛋白生产方法 |
Country Status (16)
Country | Link |
---|---|
US (6) | US5728553A (zh) |
EP (2) | EP0828759B1 (zh) |
JP (4) | JP4040088B2 (zh) |
KR (2) | KR100543612B1 (zh) |
CN (4) | CN100443499C (zh) |
AT (2) | ATE265469T1 (zh) |
AU (1) | AU698409B2 (zh) |
CA (1) | CA2220923C (zh) |
DE (2) | DE69611445T2 (zh) |
DK (2) | DK0828759T3 (zh) |
ES (2) | ES2156991T3 (zh) |
GR (1) | GR3035651T3 (zh) |
HK (2) | HK1009456A1 (zh) |
MX (1) | MX9709108A (zh) |
PT (2) | PT828759E (zh) |
WO (1) | WO1996037515A1 (zh) |
Families Citing this family (141)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2686899B1 (fr) * | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
US5728553A (en) * | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
DE19538625C2 (de) * | 1995-10-17 | 1999-08-12 | Sartorius Gmbh | Verfahren zur Abtrennung von Albumin aus Serum durch Membranionenaustauschchromatographie |
GB9526733D0 (en) * | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
US6150133A (en) * | 1996-03-13 | 2000-11-21 | Delta Biotechnology Limited | Fermentation control |
GB9902000D0 (en) | 1999-01-30 | 1999-03-17 | Delta Biotechnology Ltd | Process |
AU2007200859A1 (en) * | 1999-01-30 | 2007-03-22 | Novozymes Delta Limited | Process |
FR2792650B1 (fr) * | 1999-04-20 | 2003-02-28 | Oreal | Equivalent de peau agee, son procede de preparation et son utilisation |
ES2275992T5 (es) * | 2000-02-08 | 2011-05-18 | Allergan, Inc. | Composiciones farmacéuticas de toxina botulínica. |
US8632785B2 (en) | 2000-02-08 | 2014-01-21 | Allergan, Inc. | Clostridial toxin pharmaceutical composition containing a gelatin fragment |
US20030118598A1 (en) * | 2000-02-08 | 2003-06-26 | Allergan, Inc. | Clostridial toxin pharmaceutical compositions |
US7780967B2 (en) | 2000-02-08 | 2010-08-24 | Allergan, Inc. | Reduced toxicity Clostridial toxin pharmaceutical compositions |
US20060269575A1 (en) * | 2000-02-08 | 2006-11-30 | Allergan, Inc. | Botulinum toxin pharmaceutical compositions formulated with recombinant albumin |
EP1274720A4 (en) | 2000-04-12 | 2004-08-18 | Human Genome Sciences Inc | ALBUMIN FUSED PROTEINS |
US20050100991A1 (en) * | 2001-04-12 | 2005-05-12 | Human Genome Sciences, Inc. | Albumin fusion proteins |
DK1311269T3 (da) | 2000-08-04 | 2012-03-26 | Dmi Biosciences Inc | Fremgangsmåde til anvendelse af diketopiperaziner og sammensætning, som indeholder dem |
JP4798833B2 (ja) | 2000-10-24 | 2011-10-19 | 一般財団法人化学及血清療法研究所 | 加熱処理工程を含むヒト血清アルブミンの製造方法 |
CN1651462A (zh) * | 2000-10-24 | 2005-08-10 | 财团法人化学及血清疗法研究所 | 人血清白蛋白多聚体的单体化方法 |
JP4798832B2 (ja) * | 2000-10-24 | 2011-10-19 | 一般財団法人化学及血清療法研究所 | ヒト血清アルブミン多量体の除去方法 |
US7507413B2 (en) * | 2001-04-12 | 2009-03-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US20050054051A1 (en) * | 2001-04-12 | 2005-03-10 | Human Genome Sciences, Inc. | Albumin fusion proteins |
CA2448432A1 (en) * | 2001-06-13 | 2002-12-19 | Taurus Hsa Llc | Purification of human serum albumin |
ITBO20010426A1 (it) * | 2001-07-06 | 2003-01-06 | Alfa Wassermann Spa | Processo per la purificazione di proteine farmacologicamente attive mediante cromatografia in scambio cationico |
JP2003040798A (ja) * | 2001-07-26 | 2003-02-13 | Nihon Pharmaceutical Co Ltd | 低アルミニウム含有アルブミン製剤およびその製造法 |
US7176278B2 (en) | 2001-08-30 | 2007-02-13 | Biorexis Technology, Inc. | Modified transferrin fusion proteins |
EP1463752A4 (en) * | 2001-12-21 | 2005-07-13 | Human Genome Sciences Inc | ALBUMIN FUSION PROTEINS |
EP2277888A3 (en) | 2001-12-21 | 2011-04-27 | Human Genome Sciences, Inc. | Fusion proteins of albumin and erythropoietin |
US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
US7998986B2 (en) * | 2001-12-21 | 2011-08-16 | Exelixis Patent Company Llc | Modulators of LXR |
US20080167238A1 (en) * | 2001-12-21 | 2008-07-10 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
GB0217033D0 (en) | 2002-07-23 | 2002-08-28 | Delta Biotechnology Ltd | Gene and polypeptide sequences |
ATE520981T1 (de) * | 2002-10-02 | 2011-09-15 | Dmi Biosciences Inc | Diagnose und überwachung von krankheiten |
EP2537524B1 (en) | 2003-05-15 | 2016-07-06 | Ampio Pharmaceuticals, Inc. | Treatment of T-cell mediated diseases |
US8013611B2 (en) * | 2006-07-14 | 2011-09-06 | Reserve Power Cell, Llc | Vehicle battery product and battery monitoring system |
US7339347B2 (en) * | 2003-08-11 | 2008-03-04 | Reserve Power Cell, Llc | Apparatus and method for reliably supplying electrical energy to an electrical system |
GB0329722D0 (en) * | 2003-12-23 | 2004-01-28 | Delta Biotechnology Ltd | Modified plasmid and use thereof |
GB0329681D0 (en) | 2003-12-23 | 2004-01-28 | Delta Biotechnology Ltd | Gene expression technique |
EP1708734A4 (en) * | 2004-01-07 | 2009-06-17 | Trimeris Inc | PEPTIDES DERIVED FROM HIV GP41 HR2 AND THEIR USE IN THERAPY TO INHIBIT THE TRANSMISSION OF HUMAN IMMUNODICIENCY VIRUS |
EP1710250B1 (en) | 2004-01-20 | 2009-04-15 | Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute | Method for preparing human serum albumin through heat-treatment in presence of divalent cation |
US20060182783A1 (en) * | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Sustained release intraocular drug delivery systems |
US20070059336A1 (en) * | 2004-04-30 | 2007-03-15 | Allergan, Inc. | Anti-angiogenic sustained release intraocular implants and related methods |
WO2005110374A1 (en) * | 2004-04-30 | 2005-11-24 | Allergan, Inc. | Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component |
US8591885B2 (en) * | 2004-04-30 | 2013-11-26 | Allergan, Inc. | Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems |
AU2005317828A1 (en) | 2004-12-23 | 2006-06-29 | Novozymes Delta Limited | Gene expression technique |
CA2599731A1 (en) * | 2005-03-03 | 2006-09-08 | Dmi Biosciences, Inc. | Quantification of proteins |
US7598700B2 (en) * | 2005-03-30 | 2009-10-06 | Reserve Power Cell, Llc | Tamper resistant battery and battery warranty and performance tracking system |
MY144344A (en) * | 2005-04-08 | 2011-09-15 | Ciba Holding Inc | Adsorbents comprising anthraquinone dye-ligands for the separation of biological materials |
DE102005023155A1 (de) | 2005-05-13 | 2006-11-16 | Albutec Gmbh | Albuminlösung |
US8323666B2 (en) | 2005-08-01 | 2012-12-04 | Allergan, Inc. | Botulinum toxin compositions |
GB0518460D0 (en) * | 2005-09-09 | 2005-10-19 | Univ Nottingham Trent | Protein assay |
US7456251B2 (en) | 2006-02-02 | 2008-11-25 | Trimeris, Inc. | HIV fusion inhibitor peptides with improved biological properties |
JP2007284425A (ja) * | 2006-03-20 | 2007-11-01 | Nokodai Tlo Kk | タンパク質の精製方法 |
US8334365B2 (en) * | 2006-06-07 | 2012-12-18 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP2049560B1 (en) * | 2006-07-13 | 2013-05-15 | Novozymes Biopharma DK A/S | Process for preparing particles of proteinaceous material |
KR101193722B1 (ko) | 2006-07-24 | 2013-01-11 | 바이오렉시스 파마슈티칼 코포레이션 | 엑센딘 융합 단백질 |
US10829733B2 (en) * | 2007-01-04 | 2020-11-10 | Biolamina Ab | Composition and method for enabling proliferation of pluripotent human stem cells |
KR20100016142A (ko) * | 2007-04-03 | 2010-02-12 | 트라이머리스, 인코퍼레이티드 | 항바이러스 펩티드 치료제 전달용 신규 제제 |
CN101104635B (zh) * | 2007-04-30 | 2010-11-03 | 北京济普霖生物技术有限公司 | 一种从转基因牛乳中纯化重组人α-乳清白蛋白的方法 |
CN101835801B (zh) | 2007-08-08 | 2014-09-10 | 诺维信生物制药丹麦公司 | 转铁蛋白变体和偶联物 |
MX2010003179A (es) * | 2007-09-25 | 2010-04-30 | Trimeris Inc | Metodos de sintesis para peptidos anti-vih terapeuticos. |
US8445213B2 (en) | 2008-03-31 | 2013-05-21 | Sekisui Medical Co., Ltd. | Purified serum albumin, and immunological measurement method |
BRPI0912663A2 (pt) * | 2008-05-15 | 2016-01-26 | R Tech Ueno Ltd | composição farmacêutica para o tratamento de olho seco e/ou lesão corneal e conjuntival |
US8217047B2 (en) * | 2008-05-27 | 2012-07-10 | Dmi Acquisition Corp. | Therapeutic methods and compounds |
CA2729322C (en) | 2008-06-24 | 2020-05-26 | Technische Universitaet Muenchen | Muteins of hngal and related proteins with affinity for a given target |
SG2014012918A (en) | 2009-02-11 | 2014-04-28 | Novozymes Biopharma Dk As | Albumin variants and conjugates |
US20120315697A1 (en) * | 2009-02-20 | 2012-12-13 | Ventria Bioscience | Cell Culture Media Containing Combinations of Proteins |
DE102009013914B4 (de) * | 2009-03-19 | 2011-05-05 | Bruker Daltonik Gmbh | Kalibriersubstanzen für Atmosphärendruck-Ionenquellen |
DK2427486T3 (en) * | 2009-05-07 | 2015-05-26 | Novozymes Biopharma Dk As | A process for purifying albumin |
CA2770149A1 (en) | 2009-08-05 | 2011-02-10 | Pieris Ag | Controlled release formulations of lipocalin muteins |
CN106008697B (zh) * | 2009-08-20 | 2020-08-04 | 百深公司 | 纯化vwf以增加非-脂质包封的病毒的去除 |
RU2607374C2 (ru) | 2009-10-30 | 2017-01-10 | Новозаймс Байофарма Дк А/С | Варианты альбумина |
EP3660510A3 (en) | 2009-12-07 | 2020-07-08 | Pieris Pharmaceuticals GmbH | Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target |
AU2011207425A1 (en) * | 2010-01-25 | 2012-08-16 | Ventria Bioscience | Methods and compositions for improving protein production |
CN102939304B (zh) | 2010-04-09 | 2017-04-19 | 阿尔布麦狄克斯公司 | 白蛋白衍生物和变体 |
CN111499725A (zh) | 2010-06-08 | 2020-08-07 | 皮里斯制药有限公司 | 结合IL-4受体α的泪脂质运载蛋白突变蛋白 |
CA2808392C (en) | 2010-08-16 | 2020-03-10 | Pieris Ag | Binding proteins for hepcidin |
EP2613786A4 (en) | 2010-09-07 | 2013-10-23 | Dmi Acquisition Corp | TREATMENT OF DISEASES |
US9260492B2 (en) | 2010-11-15 | 2016-02-16 | Pieris Ag | Muteins of human lipocalin 2 with affinity for glypican-3 (GPC-3) |
EP2646552B1 (en) | 2010-12-02 | 2017-07-05 | Pieris Pharmaceuticals GmbH | Muteins of human lipocalin 2 with affinity for ctla-4 |
PL221899B1 (pl) | 2011-05-06 | 2016-06-30 | Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną | Czysta albumina oraz sposób jej otrzymywania i detekcji |
BR112014000042A2 (pt) | 2011-07-05 | 2017-02-21 | Novozymes Biopharma Dk As | composição, meio de cultura celular, uso de uma composição, e, método para cultivar células |
CN103841934A (zh) | 2011-10-10 | 2014-06-04 | 安皮奥制药股份有限公司 | 增强免疫耐受的可植入的医疗装置及其制造与植入方法 |
US8980834B2 (en) | 2011-10-10 | 2015-03-17 | Ampio Pharmaceuticals, Inc. | Treatment of degenerative joint disease |
BR112014008036A2 (pt) | 2011-10-28 | 2017-04-11 | Ampio Pharmaceuticals Inc | tratamento de rinite |
WO2013075066A2 (en) | 2011-11-18 | 2013-05-23 | Eleven Biotherapeutics, Inc. | Proteins with improved half-life and other properties |
EP3453400B1 (en) | 2011-12-13 | 2021-01-20 | Pieris Pharmaceuticals GmbH | Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors |
ES2664328T3 (es) | 2012-03-16 | 2018-04-19 | Albumedix A/S | Variantes de albúmina |
US9522940B2 (en) | 2012-05-23 | 2016-12-20 | Pieris Pharmaceuticals Gmbh | Lipocalin muteins with binding-affinity for glypican-3 (GPC-3) and use of lipocalin muteins for target-specific delivery to cells expressing GPC-3 |
US20140031527A1 (en) * | 2012-07-27 | 2014-01-30 | Csl Limited | Method for polishing albumin |
AU2013343503B2 (en) | 2012-11-08 | 2017-12-14 | Albumedix Ltd. | Albumin variants |
EP3441400B1 (en) | 2012-11-19 | 2022-07-20 | Pieris Pharmaceuticals GmbH | Novel specific-binding polypeptides and uses thereof |
US20140186447A1 (en) * | 2012-12-28 | 2014-07-03 | Abraxis Bioscience, Llc | Nanoparticle compositions of albumin and paclitaxel |
JP6128677B2 (ja) * | 2013-02-05 | 2017-05-17 | 公立大学法人大阪市立大学 | 神経細胞の遊走障害を伴う疾患の判定方法及びその利用 |
US9150629B2 (en) | 2013-03-14 | 2015-10-06 | Daiichi Sankyo Co., Ltd. | Human tear lipocalins which bind PCSK9 and methods of use thereof |
US9808454B2 (en) | 2013-03-15 | 2017-11-07 | Ampio Pharmaceuticals, Inc. | Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same |
CN103694343B (zh) * | 2013-12-26 | 2016-05-25 | 扬州艾迪生物科技有限公司 | 一种从尿液中制备人血白蛋白的方法 |
CA2936611A1 (en) | 2014-01-13 | 2015-07-16 | Pieris Pharmaceuticals Gmbh | Multi-specific polypeptide useful for localized tumor immunomodulation |
WO2015166072A1 (en) * | 2014-04-30 | 2015-11-05 | Novo Nordisk A/S | Methods for the purification of proteins using caprylic acid |
US10774119B2 (en) | 2014-05-22 | 2020-09-15 | Pieris Pharmaceuticals Gmbh | Specific-binding polypeptides and uses thereof |
KR20170045274A (ko) | 2014-08-18 | 2017-04-26 | 앰피오 파마슈티컬스 인코퍼레이티드 | 관절 징후의 치료 |
CN104628830A (zh) * | 2015-01-23 | 2015-05-20 | 深圳康泰生物制品股份有限公司 | 重组酿酒酵母表达HBsAg的制备工艺及其分离纯化工艺、HBsAg和乙肝疫苗 |
CA2973640A1 (en) | 2015-01-28 | 2016-08-04 | Rachida Siham Bel Aiba | Novel proteins specific for angiogenesis |
SG11201706621SA (en) | 2015-02-18 | 2017-09-28 | Sanofi Sa | Novel proteins specific for pyoverdine and pyochelin |
US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
JP6783797B2 (ja) | 2015-05-04 | 2020-11-11 | ピエリス ファーマシューティカルズ ゲーエムベーハー | 抗がん融合ポリペプチド |
DK3292137T3 (da) | 2015-05-04 | 2022-10-17 | Pieris Pharmaceuticals Gmbh | Proteiner specifikke for cd137 |
MX2017014730A (es) | 2015-05-18 | 2018-06-28 | Pieris Pharmaceuticals Gmbh | Muteinas de lipocalina 2 humana con afinidad por glipicano-3 (gpc3). |
RU2754466C2 (ru) | 2015-05-18 | 2021-09-02 | ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ | Слитый полипептид с противораковой активностью |
WO2016209969A1 (en) | 2015-06-22 | 2016-12-29 | Ampio Pharmaceuticals, Inc. | Use of low molecular weight fractions of human serum albumin in treating diseases |
EP3115371A1 (en) | 2015-07-07 | 2017-01-11 | Sanofi | Fusion molecules |
CN108348573A (zh) | 2015-07-15 | 2018-07-31 | 皮里斯制药有限公司 | Lag-3特异性的新型蛋白 |
CN108137674B (zh) | 2015-08-20 | 2022-12-06 | 阿尔布梅迪克斯医疗有限公司 | 白蛋白变体和缀合物 |
FR3040882A1 (fr) * | 2015-09-10 | 2017-03-17 | Lab Francais Du Fractionnement | Composition liquide d'albumine humaine a usage therapeutique |
US10703810B2 (en) | 2015-11-30 | 2020-07-07 | Pieris Australia Pty Ltd. | Fusion polypeptides which bind vascular endothelial growth factor a (VEGF-A) and angiopoietin-2 (Ang-2) |
TW201725212A (zh) | 2015-12-10 | 2017-07-16 | 第一三共股份有限公司 | 特異性於降鈣素基因相關胜肽的新穎蛋白 |
EP3394243A1 (en) | 2015-12-22 | 2018-10-31 | Albumedix Ltd. | Improved protein expression strains |
KR102050852B1 (ko) * | 2016-03-11 | 2019-12-03 | 주식회사 스템온 | 세포 리프로그래밍 장치 |
KR102457855B1 (ko) * | 2016-08-17 | 2022-10-25 | 베링거 인겔하임 인터내셔날 게엠베하 | 생체 분자를 함유하는 고농축 액상 제형의 제조 방법 |
JP6928084B2 (ja) | 2016-10-04 | 2021-09-01 | アルブミディクス リミティド | 組換え酵母由来血清アルブミンの使用 |
WO2018087108A1 (en) | 2016-11-09 | 2018-05-17 | Pieris Pharmaceuticals Gmbh | Proteins specific for cd137 |
KR20190104409A (ko) | 2017-01-18 | 2019-09-09 | 피어이스 파마슈티컬즈 게엠베하 | Lag-3에 대하여 결합 친화성을 갖는 리포칼린 뮤테인 |
AU2018233184B2 (en) * | 2017-03-16 | 2022-06-16 | Evolve Biologics Inc. | Method for purification of albumin |
CN111032871A (zh) | 2017-06-20 | 2020-04-17 | 阿尔布梅迪克斯医疗有限公司 | 改良的表达蛋白质的菌株 |
WO2019199476A1 (en) * | 2018-04-12 | 2019-10-17 | Amgen Inc. | Methods for making stable protein compositions |
CN110563833A (zh) * | 2018-06-06 | 2019-12-13 | 中国计量科学研究院 | 一种人血白蛋白标准物质原料的制备方法及其产品和应用 |
RS64343B9 (sr) | 2018-07-31 | 2023-11-30 | Pieris Pharmaceuticals Gmbh | Novi fuzioni protein specifičan za cd137 i pd-l1 |
CN109734796B (zh) * | 2019-02-01 | 2022-04-15 | 广州蕊特生物科技有限公司 | 一种从溶血血清中分离白蛋白的工艺 |
CN109776673B (zh) * | 2019-02-20 | 2022-03-29 | 天津理工大学 | 一种适合中试量产的高纯度牛血清白蛋白纯化工艺 |
AU2020229436A1 (en) | 2019-02-26 | 2021-07-01 | Pieris Pharmaceuticals Gmbh | Novel fusion proteins specific for CD137 and GPC3 |
CN110229229A (zh) * | 2019-07-10 | 2019-09-13 | 甘肃养泰和生物科技有限公司 | 一种从牛血浆中提取纯化细胞培养级牛血清白蛋白的生产方法及其应用 |
AU2020375810A1 (en) | 2019-10-28 | 2022-05-12 | Abraxis Bioscience, Llc | Pharmaceutical compositions of albumin and rapamycin |
WO2021245240A1 (en) | 2020-06-05 | 2021-12-09 | Pieris Pharmaceuticals Gmbh | Multimeric immunomodulator targeting 4-1bb |
US11739166B2 (en) | 2020-07-02 | 2023-08-29 | Davol Inc. | Reactive polysaccharide-based hemostatic agent |
WO2022120547A1 (zh) | 2020-12-08 | 2022-06-16 | 通化安睿特生物制药股份有限公司 | 纯化重组蛋白的方法 |
WO2022214649A1 (en) | 2021-04-08 | 2022-10-13 | Pieris Pharmaceuticals Gmbh | Novel lipocalin muteins specific for connective tissue growth factor (ctgf) |
WO2022243341A1 (en) | 2021-05-18 | 2022-11-24 | Pieris Pharmaceuticals Gmbh | Lipocalin muteins with binding affinity for ox40 |
CN113735963A (zh) * | 2021-09-10 | 2021-12-03 | 山东健通生物科技有限公司 | 一种重组人血清白蛋白纯化过程去除色素的方法 |
CN114316088B (zh) * | 2021-12-22 | 2022-09-09 | 中国水产科学研究院黄海水产研究所 | 亲和树脂、制备方法及其在分离纯化藻蓝蛋白中的应用 |
WO2024064713A1 (en) | 2022-09-21 | 2024-03-28 | Seagen Inc. | Novel fusion protein specific for cd137 and cd228 |
CN116120392B (zh) * | 2023-04-18 | 2023-08-01 | 上海健士拜生物科技有限公司 | 聚体蛋白的纯化方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0570916A2 (en) * | 1992-05-20 | 1993-11-24 | The Green Cross Corporation | Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same |
WO1994003626A1 (en) * | 1992-07-31 | 1994-02-17 | The Green Cross Corporation | Method of highly purifying human serum albumin |
CN1087914A (zh) * | 1992-12-11 | 1994-06-15 | 上海莱士血制品有限公司 | 白蛋白的纯化方法 |
EP0612761A1 (en) * | 1993-02-25 | 1994-08-31 | The Green Cross Corporation | Human serum albumin and process for producing the same |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9019919D0 (en) * | 1990-09-12 | 1990-10-24 | Delta Biotechnology Ltd | Purification of proteins |
US2433905A (en) | 1943-11-01 | 1948-01-06 | Jr Walter L Hughes | Method for the crystallization of albumin and the preparation of protein products therefrom |
AT317418B (de) * | 1972-06-16 | 1974-08-25 | Brigitte Panhofer | Verfahren zur Herstellung von intravenös beim Menschen anwendbarem Humanalbumin aus menschlichen Placenten |
FR2190437B1 (zh) | 1972-07-05 | 1975-08-08 | Merieux Inst | |
CA1044537A (en) | 1973-05-09 | 1978-12-19 | Amf Incorporated | Filter medium and process |
DE2537123A1 (de) * | 1975-08-20 | 1977-03-03 | New Zealand Inventions Dev | Verfahren zur herstellung von albumin |
SE405549B (sv) * | 1975-10-09 | 1978-12-18 | Pharmacia Fine Chemicals Ab | Forfarande for isolering av albumin ur plasmaprodukter genom kromatografisk fraktionering |
US4043997A (en) * | 1976-05-28 | 1977-08-23 | Cutter Laboratories, Inc. | Method for isolating albumin using insoluble supports coupled to a dye |
US4075197A (en) * | 1976-09-20 | 1978-02-21 | Monsanto Company | Serum albumin production |
IN150740B (zh) | 1978-11-24 | 1982-12-04 | Hoffmann La Roche | |
US4228154A (en) * | 1979-02-26 | 1980-10-14 | Armour Pharmaceutical Company | Purification of plasma albumin by ion exchange chromatography |
US4222934A (en) * | 1979-04-12 | 1980-09-16 | American National Red Cross | Preparation of albumin using ethanol |
GB2053926B (en) | 1979-07-20 | 1983-02-23 | Atkinson A | Albumin extraction by affinity chromatography |
US4350156A (en) * | 1980-05-29 | 1982-09-21 | Japan Foundation For Artificial Organs | Method and apparatus for on-line filtration removal of macromolecules from a physiological fluid |
IL66614A (en) * | 1981-08-28 | 1985-09-29 | Genentech Inc | Method of constructing a dna sequence encoding a polypeptide,microbial production of human serum albumin,and pharmaceutical compositions comprising it |
US4391801A (en) | 1981-10-29 | 1983-07-05 | Cutter Laboratories, Inc. | Plasma protein fraction substantially free of acetate ions |
FR2543448A1 (fr) * | 1983-04-01 | 1984-10-05 | Rhone Poulenc Spec Chim | Procede de fractionnement du plasma |
US4748120A (en) * | 1983-05-02 | 1988-05-31 | Diamond Scientific Co. | Photochemical decontamination treatment of whole blood or blood components |
DE3344656A1 (de) * | 1983-12-09 | 1985-06-13 | Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München | Verfahren zur herstellung einer serumproteinloesung |
CA1286622C (en) * | 1986-04-28 | 1991-07-23 | Chokyun Rha | Method for clarifying and stabilizing cell culture media |
JPS62294621A (ja) | 1986-06-13 | 1987-12-22 | Green Cross Corp:The | アルブミンの回収方法 |
JPS6383100A (ja) * | 1986-09-26 | 1988-04-13 | Green Cross Corp:The | ヒト尿中アルブミンの製造方法 |
US4833233A (en) | 1987-08-20 | 1989-05-23 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Human serum albumin crystals and method of preparation |
IL88326A (en) | 1987-11-18 | 1993-03-15 | Gist Brocades Nv | Purification of serum albumin |
US4990447A (en) * | 1988-06-24 | 1991-02-05 | Gist-Brocades Nv | Process for the purification of serum albumin |
FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
JP3554796B2 (ja) * | 1988-10-31 | 2004-08-18 | 三菱ウェルファーマ株式会社 | アルブミン製剤及びその製造方法 |
US4891221A (en) * | 1988-11-23 | 1990-01-02 | Edward Shanborm | Whole blood antiviral process and composition |
FR2648048B1 (fr) * | 1989-06-08 | 1994-06-03 | Lille Transfusion Sanguine | Procede de preparation de solutions d'albumine purifiee |
GB8913586D0 (en) | 1989-06-13 | 1989-08-02 | Technicol Limited | A method of determining the glycosylated protein level of a sample and an apparatus for use in the method |
JPH0768137B2 (ja) * | 1989-06-15 | 1995-07-26 | 株式会社ミドリ十字 | アルブミン製剤及びその製法 |
SE500110C2 (sv) | 1989-06-27 | 1994-04-18 | Kabi Pharmacia Ab | Sätt att rena ett protein från därtill bundna flervärda metalljoner |
JPH0671434B2 (ja) | 1989-09-18 | 1994-09-14 | 株式会社ミドリ十字 | ヒト血清アルブミンの製造方法 |
CA2022165C (en) | 1989-10-05 | 1999-11-23 | Chong E. Chang | Albumin purification |
US5250662A (en) * | 1989-10-05 | 1993-10-05 | Alpha Therapeutic Corporation | Albumin purification |
ATE269872T1 (de) * | 1990-04-19 | 2004-07-15 | Bayer Ag | Methode zur herstellung von im wesentlichen monomeren normalen menschlichen serum-albumin |
JP3230091B2 (ja) * | 1990-06-25 | 2001-11-19 | ウェルファイド株式会社 | ヒト血清アルブミンの着色抑制方法 |
JP2982296B2 (ja) | 1990-11-19 | 1999-11-22 | 吉富製薬株式会社 | アルブミン含有水溶液の精製法 |
JP2949846B2 (ja) * | 1990-11-30 | 1999-09-20 | 吉富製薬株式会社 | アルブミン製剤の保存方法 |
FR2672604B1 (fr) | 1991-02-07 | 1995-05-05 | Pasteur Merieux Serums Vacc | Procede pour isoler de l'albumine humaine a partir du surnageant iv, notamment iv-4, ou de la fraction v de cohn ou d'un surnageant ou fraction analogue. |
US5284777A (en) * | 1991-03-04 | 1994-02-08 | Isolab, Inc. | Combined glycated hemoglobin and immunoturbidometric glycated albumin assay from whole blood lysate |
US5330901A (en) * | 1991-04-26 | 1994-07-19 | Research Corporation Technologies, Inc. | Expression of human serum albumin in Pichia pastoris |
IE20000781A1 (en) * | 1991-07-12 | 2001-02-21 | Dsm Nv | Process for the purification of serum albumin |
FR2686620B1 (fr) * | 1992-01-27 | 1995-06-23 | Rhone Poulenc Rorer Sa | Serum-albumine humaine, preparation et utilisation. |
US5281582A (en) * | 1992-02-27 | 1994-01-25 | Alliance Pharmaceuticals, Corp. | Serum growth factor |
DE4226971C2 (de) | 1992-08-14 | 1997-01-16 | Widmar Prof Dr Tanner | Modifizierte Pilzzellen und Verfahren zur Herstellung rekombinanter Produkte |
US5728553A (en) * | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
SE9301583D0 (sv) | 1993-05-07 | 1993-05-07 | Kabi Pharmacia Ab | Yeast strain and methods for expressing heterologous proteins in yeast |
JP3702474B2 (ja) | 1994-06-01 | 2005-10-05 | 三菱ウェルファーマ株式会社 | 血清アルブミン製剤の製造方法 |
CA2157219C (en) * | 1994-08-31 | 2010-10-05 | Munehiro Noda | Process for purifying recombinant human serum albumin |
JPH09209303A (ja) | 1996-02-05 | 1997-08-12 | Hokkaido Supuritsuton Kogyo Kk | 舗装ブロック |
AU4837996A (en) | 1996-02-29 | 1997-09-16 | Delta Biotechnology Limited | High purity albumin production process |
-
1995
- 1995-05-25 US US08/378,859 patent/US5728553A/en not_active Expired - Lifetime
-
1996
- 1996-02-29 CN CNB2006101006176A patent/CN100443499C/zh not_active Expired - Lifetime
- 1996-02-29 AT AT00201960T patent/ATE265469T1/de active
- 1996-02-29 DK DK96904190T patent/DK0828759T3/da active
- 1996-02-29 DE DE69611445T patent/DE69611445T2/de not_active Expired - Lifetime
- 1996-02-29 EP EP96904190A patent/EP0828759B1/en not_active Expired - Lifetime
- 1996-02-29 CN CNB2004100575838A patent/CN100455597C/zh not_active Expired - Lifetime
- 1996-02-29 CA CA002220923A patent/CA2220923C/en not_active Expired - Lifetime
- 1996-02-29 WO PCT/GB1996/000449 patent/WO1996037515A1/en not_active Application Discontinuation
- 1996-02-29 AT AT96904190T patent/ATE198482T1/de active
- 1996-02-29 EP EP00201960A patent/EP1031578B1/en not_active Expired - Lifetime
- 1996-02-29 CN CNB961958243A patent/CN1198844C/zh not_active Expired - Lifetime
- 1996-02-29 DE DE69632353T patent/DE69632353T2/de not_active Expired - Lifetime
- 1996-02-29 US US08/952,558 patent/US6638740B1/en not_active Expired - Fee Related
- 1996-02-29 PT PT96904190T patent/PT828759E/pt unknown
- 1996-02-29 KR KR1020047011825A patent/KR100543612B1/ko not_active IP Right Cessation
- 1996-02-29 AU AU48380/96A patent/AU698409B2/en not_active Ceased
- 1996-02-29 DK DK00201960T patent/DK1031578T3/da active
- 1996-02-29 PT PT00201960T patent/PT1031578E/pt unknown
- 1996-02-29 JP JP53545796A patent/JP4040088B2/ja not_active Expired - Lifetime
- 1996-02-29 ES ES96904190T patent/ES2156991T3/es not_active Expired - Lifetime
- 1996-02-29 CN CN03127743A patent/CN100584857C/zh not_active Expired - Lifetime
- 1996-02-29 ES ES00201960T patent/ES2219257T3/es not_active Expired - Lifetime
- 1996-02-29 KR KR1019970708469A patent/KR100566606B1/ko not_active IP Right Cessation
-
1997
- 1997-11-14 US US08/970,648 patent/US6034221A/en not_active Expired - Lifetime
- 1997-11-25 MX MX9709108A patent/MX9709108A/es unknown
-
1998
- 1998-08-26 HK HK98110246A patent/HK1009456A1/xx not_active IP Right Cessation
-
2001
- 2001-03-29 GR GR20010400501T patent/GR3035651T3/el unknown
-
2002
- 2002-05-31 JP JP2002160250A patent/JP4037174B2/ja not_active Expired - Lifetime
- 2002-11-21 US US10/301,357 patent/US20030187226A1/en not_active Abandoned
-
2004
- 2004-06-22 US US10/873,504 patent/US7223561B2/en not_active Expired - Fee Related
-
2005
- 2005-06-15 HK HK05105030.6A patent/HK1072436A1/xx not_active IP Right Cessation
-
2006
- 2006-07-04 JP JP2006184756A patent/JP4372772B2/ja not_active Expired - Lifetime
-
2007
- 2007-04-23 US US11/738,582 patent/US7601515B2/en not_active Expired - Fee Related
- 2007-07-30 JP JP2007197742A patent/JP4372813B2/ja not_active Expired - Lifetime
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0570916A2 (en) * | 1992-05-20 | 1993-11-24 | The Green Cross Corporation | Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same |
WO1994003626A1 (en) * | 1992-07-31 | 1994-02-17 | The Green Cross Corporation | Method of highly purifying human serum albumin |
CN1087914A (zh) * | 1992-12-11 | 1994-06-15 | 上海莱士血制品有限公司 | 白蛋白的纯化方法 |
EP0612761A1 (en) * | 1993-02-25 | 1994-08-31 | The Green Cross Corporation | Human serum albumin and process for producing the same |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100455597C (zh) | 高纯度白蛋白生产方法 | |
KR0153516B1 (ko) | 폴리펩티드 | |
JPH11509525A (ja) | 高純度アルブミンの製造方法 | |
Kobayashi et al. | The development of recombinant human serum albumin | |
US20120165509A1 (en) | method for isolating and purifying recombinant human serum albumin from transgenic rice grain | |
JPH0646873A (ja) | ヒト血清アルブミンの高度精製方法 | |
WO1997031947A1 (en) | High purity albumin production process | |
JP2869417B2 (ja) | 遺伝子操作により得られるヒト血清アルブミン | |
JPH11191A (ja) | 遺伝子操作により得られるヒト血清アルブミン | |
Bohner | Expression, purification, crystallization and structure determination of herpes simplex virus type 1 thymidine kinase | |
CN1382798A (zh) | 一种多肽——二磷酸腺苷核糖二磷酸酶-38.5以及具有这个二磷酸腺苷核糖二磷酸酶的药学化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1072436 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1072436 Country of ref document: HK |
|
C56 | Change in the name or address of the patentee |
Owner name: NOWISON DARTA CO., LTD. Free format text: FORMER NAME: DELTA BIOTECHNOLOGY CO., LTD. Owner name: NOVOZYMES UK BIO-PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: NOWISON DARTA CO., LTD. |
|
CP03 | Change of name, title or address |
Address after: British Nottinghamshire Patentee after: NOVOZYMES BIOPHARMA DK A/S Address before: British Nottinghamshire Patentee before: NOVOZYMES DELTA LTD. Address after: British Nottinghamshire Patentee after: NOVOZYMES DELTA LTD. Address before: British Nottinghamshire Patentee before: Delta Biotechnology Ltd. |
|
ASS | Succession or assignment of patent right |
Owner name: NOVOZYMES BIOPOLYMER AS Free format text: FORMER OWNER: NOVOZYMES BIOPHARMA UK CO., LTD. Effective date: 20100919 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: NOTTINGHAMSHIRE, UK TO: BAGSVAERD, DENMARK |
|
TR01 | Transfer of patent right |
Effective date of registration: 20100919 Address after: Denmark bagsvaerd Patentee after: NOVOZYMES BIOPHARMA DK A/S Address before: British Nottinghamshire Patentee before: NOVOZYMES BIOPHARMA DK A/S |
|
CX01 | Expiry of patent term |
Granted publication date: 20090128 |
|
EXPY | Termination of patent right or utility model |